Merck

Biopharma's stock market winners of 2022 revealed
EP Vantage
Wed, 01/18/23 - 09:46 am
pharma stocks
Merck
Eli Lilly
AbbVie
Daiichi Sankyo
Vertex Pharmaceuticals
Takeda
Sarepta Therapeutics
Halozyme
Horizon Therapeutics
Chasing Roche, Merck talks up subcutaneous Keytruda ahead of phase 3 data drop
Fierce Pharma
Mon, 01/16/23 - 11:16 am
Merck
Keytruda
Roche
cancer
oncology
Big caps bounce back for biopharma
EP Vantage
Mon, 01/16/23 - 11:14 am
pharma stocks
Amgen
BeiGene
Bristol Myers Squibb
Gilead Sciences
Lantheus Holdings
Madrigal Pharmaceuticals
Merck
Moderna Therapeutics
Novo Nordisk
Prometheus Biosciences
Roche
Three TIGIT players look to surprise in 2023
EP Vantage
Fri, 01/13/23 - 10:06 am
anti-TIGIT
Roche
Merck
Gilead Sciences
Arcus Biosciences
Biopharma’s bolt-on bonanza is set to continue
EP Vantage
Thu, 01/12/23 - 10:18 am
M&A
Amgen
AstraZeneca
Bristol Myers Squibb
GSK
Ipsen
Merck
Pfizer
Merck Highlights Growth Strategy at J.P. Morgan
BioSpace
Tue, 01/10/23 - 06:48 pm
Merck
JPMHC 2023
Keytruda
vaccines
M&A
JPM23, Day 2: Takeda readies for dengue vaccine launch; Merck touts recent deals
Fierce Pharma
Tue, 01/10/23 - 10:50 am
JPMHC 2023
Takeda
vaccines
Roche
GSK
Bayer
Merck
Novo Nordisk, AstraZeneca and Lilly will top pharma's revenue growth in 2023: report
Fierce Pharma
Sun, 01/8/23 - 09:57 pm
Pfizer
Merck
JNJ
Novo Nordisk
AstraZeneca
The biggest-selling pharma companies of 2023
EP Vantage
Wed, 01/4/23 - 05:20 pm
Pfizer
Merck
JNJ
Novartis
AbbVie
Roche
Lilly, Merck double down on peptide-targeted drug delivery, betting billions in biobucks on PeptiDream pacts
Fierce Pharma
Tue, 01/3/23 - 10:10 am
Eli Lilly
Merck
PeptiDreams
peptides
drug delivery
ADC deals: Mersana engages with Merck, LegoChem and Amgen collaborate
Biopharma Reporter
Mon, 01/2/23 - 06:41 pm
antibody-drug conjugate
Merck
LegoChem Biosciences
Mersana
Amgen
GSK
Janssen
OncoC4 doses first participant in ovarian cancer therapy trial
Clinical Trials Arena
Mon, 01/2/23 - 06:33 pm
OncoC4
clinical trials
ONC-392
Merck
Keytruda
ovarian cancer
platinum-resistant ovarian cancer
Merck Expands ADC Footprint with $9.3B Kelun Licensing Deal
BioSpace
Thu, 12/22/22 - 10:44 am
Merck
China
Kelun-Biotech
antibody-drug conjugate
oncology
AstraZeneca, Merck's Lynparza wins EU nod in advanced prostate cancer right after FDA delay
Fierce Pharma
Wed, 12/21/22 - 12:40 pm
AstraZeneca
Merck
Lynparza
Europe
prostate cancer
advanced prostate cancer
Merck & Co. bails on NGM eye disease collab in wake of phase 2 fail
Fierce Biotech
Wed, 12/21/22 - 11:29 am
Merck
NGM Biopharmaceuticals
clinical trials
eye disease
NGM621
geographic atrophy
AstraZeneca, Merck hit with 3-month delay for Lynparza's FDA filing in first-line prostate cancer
Fierce Pharma
Thu, 12/15/22 - 11:01 am
AstraZeneca
Merck
Lynparza
FDA
metastatic castration-resistant prostate cancer
Moderna, Merck & Co. mRNA cancer vaccine slashes melanoma recurrence in Keytruda combo trial
Fierce Biotech
Tue, 12/13/22 - 10:35 am
Merck
Moderna Therapeutics
MRNA
cancer immunotherapy
Keytruda
melanoma
Merck initiates cash tender offer to buy Imago BioSciences
Pharmaceutical Business Review
Tue, 12/13/22 - 10:26 am
Merck
M&A
Imago BioSciences
Setting the Stage for ASH 2022
BioSpace
Fri, 12/9/22 - 10:50 am
ASH 2022
AstraZeneca
Janssen
Merck
Vega Therapeutics
Mirati to focus adagrasib/Keytruda study in low PDL1 lung cancer patients
Yahoo/Reuters
Tue, 12/6/22 - 10:21 am
Mirati Therapeutics
adagrasib
Merck
Keytruda
metastatic lung cancer
lung cancer

Pages